The role of 68 Ga-DOTATATE PET/CT and 18 F-FDG PET/CT in the follow-up of patients with medullary thyroid cancer

Medullary thyroid cancer (MTC) is an aggressive form of thyroid malignancy with local metastasis in 30%-50% of the cases and distant metastasis predominantly to lung, liver and skeleton in 13%-15% of patients. Identification of the lesion using imaging modalities is of crucial importance for disease...

Full description

Saved in:
Bibliographic Details
Published inHellenic journal of nuclear medicine Vol. 23; no. 3; p. 321
Main Authors Şahin, Onur Erdem, Uslu-Beşli, Lebriz, Asa, Sertaç, Sağer, Sait, Sönmezoğlu, Kerim
Format Journal Article
LanguageEnglish
Published Greece 01.09.2020
Subjects
Adult
Aged
Carcinoma, Neuroendocrine - diagnostic imaging
Female
Fluorodeoxyglucose F18
Follow-Up Studies
Humans
Male
Middle Aged
Organometallic Compounds
Positron Emission Tomography Computed Tomography - methods
Retrospective Studies
Thyroid Neoplasms - diagnostic imaging
Young Adult
Online AccessGet full text

Cover

More Information
Summary:Medullary thyroid cancer (MTC) is an aggressive form of thyroid malignancy with local metastasis in 30%-50% of the cases and distant metastasis predominantly to lung, liver and skeleton in 13%-15% of patients. Identification of the lesion using imaging modalities is of crucial importance for disease management in the recurrent or metastatic MTC. In this study, we aimed to determine the efficacy of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography ( F-FDG PET/CT) and gallium-68 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid tyrosine-3-octreotate ( Ga-DOTATATE) PET/CT imaging in patients with MTC and to evaluate the relationship between imaging findings and serum tumor markers. The records of MTC patients, who were treated and followed-up in our department between the years 2005 and 2018 were retrospectively analyzed. Seventy-three patients with MTC, who underwent either Ga-DOTATATE PET/CT (n=61) and/or F-FDG PET/CT (n=59) together with serum calcitonin (Ctn) and/or carcinoembryogenic antigen (CEA) measurement within 6 months period were included in the study. Gallium-68-DOTATATE PET/CT and F-FDG PET/CT scans performed within 6 months on the same patient (n=38) were analyzed separately for comparison of the efficacy of both modalities. The overall sensitivity of F-FDG PET/CT and Ga-DOTATATE PET/CT were 72.4% and 88.1%, respectively in detecting recurrent or metastatic disease. In the group of patients, who had both F-FDG PET/CT and Ga-DOTATATE PET/CT within 6 months interval (median: 1.14 months; range: 0.03 - 5.7 months), no significant difference was found in the overall sensitivity of both imaging modalities, however Ga-DOTATATE PET/CT was found to be more sensitive in detection of bone lesions compared to F-FDG PET/CT (P=0.005). Both F-FDG PET/CT and Ga-DOTATATE PET/CT are efficient imaging modalities in detection of recurrent or metastatic disease in MTC patients. Gallium-68-DOTATATE PET/CT could be more beneficial in detection of bone metastases with respect to F-FDG PET/CT.
ISSN:1790-5427